Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications
Targeted cellular and immunotherapies have welcomed a new chapter in multi-modal cancer therapy. These agents harness our innate immune system and destroy malignant cells in a precise way as compared with “legacy” chemotherapeutic agents that largely rely on abolishing cell division. New therapies c...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/8/554 |
| _version_ | 1797585051370651648 |
|---|---|
| author | Alessandro De Camilli Gregory Fischer |
| author_facet | Alessandro De Camilli Gregory Fischer |
| author_sort | Alessandro De Camilli |
| collection | DOAJ |
| description | Targeted cellular and immunotherapies have welcomed a new chapter in multi-modal cancer therapy. These agents harness our innate immune system and destroy malignant cells in a precise way as compared with “legacy” chemotherapeutic agents that largely rely on abolishing cell division. New therapies can augment the T-cell recognition of tumor antigens and effectively prevent tumor cells from their historically successful ability to evade immune recognition. These novel agents cause acute and chronic toxicities to a variety of organ systems (enteritis, pneumonitis, hypophysitis, and hepatitis), and this may masquerade as other chronic illnesses or paraneoplastic effects. As the perioperative footprint of cancer patients increases, it is essential that perioperative providers—anesthesiologists, surgeons, nurse anesthetists, and inpatient hospital medicine providers—be up to date on the physiologic mechanisms that underlie these new therapies as well as their acute and subacute toxicity profiles. Immunotherapy toxicity can significantly impact perioperative morbidity as well as influence perioperative management, such as prophylaxis for adrenal insufficiency, preoperative pulmonary assessment, and screening for thyroid dysfunction, among others. |
| first_indexed | 2024-03-11T00:00:19Z |
| format | Article |
| id | doaj.art-793e50abe2bd432ebb444bc15506c77e |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T00:00:19Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-793e50abe2bd432ebb444bc15506c77e2023-11-19T00:46:47ZengMDPI AGCurrent Oncology1198-00521718-77292023-08-013087638765310.3390/curroncol30080554Novel Cellular and Immunotherapy: Toxicities and Perioperative ImplicationsAlessandro De Camilli0Gregory Fischer1Memorial Sloan Kettering, 1275 York Avenue, New York, NY 10065, USAMemorial Sloan Kettering, 1275 York Avenue, New York, NY 10065, USATargeted cellular and immunotherapies have welcomed a new chapter in multi-modal cancer therapy. These agents harness our innate immune system and destroy malignant cells in a precise way as compared with “legacy” chemotherapeutic agents that largely rely on abolishing cell division. New therapies can augment the T-cell recognition of tumor antigens and effectively prevent tumor cells from their historically successful ability to evade immune recognition. These novel agents cause acute and chronic toxicities to a variety of organ systems (enteritis, pneumonitis, hypophysitis, and hepatitis), and this may masquerade as other chronic illnesses or paraneoplastic effects. As the perioperative footprint of cancer patients increases, it is essential that perioperative providers—anesthesiologists, surgeons, nurse anesthetists, and inpatient hospital medicine providers—be up to date on the physiologic mechanisms that underlie these new therapies as well as their acute and subacute toxicity profiles. Immunotherapy toxicity can significantly impact perioperative morbidity as well as influence perioperative management, such as prophylaxis for adrenal insufficiency, preoperative pulmonary assessment, and screening for thyroid dysfunction, among others.https://www.mdpi.com/1718-7729/30/8/554immunotherapycellular therapyperioperative riskhypophysitispneumonitis |
| spellingShingle | Alessandro De Camilli Gregory Fischer Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications Current Oncology immunotherapy cellular therapy perioperative risk hypophysitis pneumonitis |
| title | Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications |
| title_full | Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications |
| title_fullStr | Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications |
| title_full_unstemmed | Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications |
| title_short | Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications |
| title_sort | novel cellular and immunotherapy toxicities and perioperative implications |
| topic | immunotherapy cellular therapy perioperative risk hypophysitis pneumonitis |
| url | https://www.mdpi.com/1718-7729/30/8/554 |
| work_keys_str_mv | AT alessandrodecamilli novelcellularandimmunotherapytoxicitiesandperioperativeimplications AT gregoryfischer novelcellularandimmunotherapytoxicitiesandperioperativeimplications |